OTC Markets OTCPK - Delayed Quote USD

GlobeStar Therapeutics Corporation (GSTC)

Compare
0.0004 0.0000 (0.00%)
At close: October 21 at 3:35 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. James C. Katzaroff President, CEO, Secretary, Principal Executive Officer & Chairman of the Board 180k -- 1957
Mr. Robert R. Hale Chicoski CPA CFO, Treasurer, Secretary, Principal Financial & Accounting Officer 84k -- 1943
Ms. Brooke Greenwald Chief Marketing Officer -- -- --
Mr. David Croom Executive Vice President -- -- --

GlobeStar Therapeutics Corporation

719 Jadewin Avenue
Richland, WA 99352
United States
206 451 1970 https://www.globestartherapeutics.com
Sector:?
Healthcare
Industry:?
Biotechnology

Description

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.

Corporate Governance

GlobeStar Therapeutics Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

October 11, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 14, 2024 at 12:00 AM UTC

NT 10-Q: Periodic Financial Reports

June 28, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 17, 2024 at 12:00 AM UTC

NT 10-Q: Periodic Financial Reports

March 12, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

February 15, 2024 at 12:00 AM UTC

NT 10-Q: Periodic Financial Reports

January 19, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

January 2, 2024 at 12:00 AM UTC

NT 10-K: Periodic Financial Reports

November 13, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 17, 2023 at 12:00 AM UTC

10-Q: Periodic Financial Reports

Related Tickers